Search
BF-1
go.drugbank.com/drugs/DB06029ExperimentalBF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.
NP2
go.drugbank.com/drugs/DB06308InvestigationalIt was under investigation in clinical trial NCT01291901 (NP2 Enkephalin For Treatment of Intractable Cancer Pain). … NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin.
1D09C3
go.drugbank.com/drugs/DB05121Experimental1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. … class II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a functioning immune system for its cell-killing
MF101
go.drugbank.com/drugs/DB05052InvestigationalMF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation … MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women.
Aminacrine
go.drugbank.com/drugs/DB11561InvestigationalA highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.
Categories: Compounds used in a research, industrial, or household settingGallium maltolate
go.drugbank.com/drugs/DB05420InvestigationalGallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.
XL228
go.drugbank.com/drugs/DB05184InvestigationalXL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation
GlycoPEG-GCSF
go.drugbank.com/drugs/DB06022ExperimentalGlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.
NNZ-2591
go.drugbank.com/drugs/DB15601InvestigationalIt was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … NNZ-2591 (cyclo-L-glycyl-L-2-allylproline)[A189390] is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been
Synonyms: Cyclo(-L-glycyl-L-2-allylproline), Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-8a-(2-propenyl)-, (8aR)-